Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › rivaroxaban

rivaroxaban

16 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of rivaroxaban

48 trials tracked of rivaroxaban: 26 in phase 3 or 4 and 12 with published results. The most-cited published study has 2447 citations.

48Trials tracked
26Phase 3 & 4
0Recruiting
12With published results
Phase distribution
Phase 4 5 Phase 3 21 Phase 2 11 Phase 1 3 Other / NA 8
  1. Phase 3 Rivaroxaban for the Prevention of Major Cardiovascular Events in Coronary or Peripheral Artery Disease Completed · 2,447 cited
  2. Phase 3 A Study to Evaluate the Efficacy and Safety of Rivaroxaban Venous Thromboembolism (VTE) Prophylaxis in Ambulatory Cancer Participants Completed · 725 cited
  3. Phase 3 EINSTEIN Junior: Oral Rivaroxaban in Children With Venous Thrombosis Completed · 331 cited
  4. Phase 3 Comparison of a Rivaroxaban-based Strategy With an Antiplatelet-based Strategy Following Successful TAVR for the Prevention of Leaflet Thickening and Reduced Leaflet Motion as Evaluated by Four-dimensional, Volume-rendered Computed Tomography (4DCT) Completed · 287 cited
  5. Phase 3 Superficial Vein Thrombosis (SVT) Treated With Rivaroxaban Versus Fondaparinux Completed · 177 cited
  6. Phase 3 A Study to Assess the Effectiveness and Safety of Rivaroxaban in Reducing the Risk of Death, Myocardial Infarction or Stroke in Participants With Heart Failure and Coronary Artery Disease Following an Episode of Decompensated Heart Failure Completed · 98 cited
Show 42 more trials
  1. Phase 3 Pharmacokinetic, Pharmacodynamic, Safety, and Efficacy Study of Rivaroxaban for Thromboprophylaxis in Pediatric Participants 2 to 8 Years of Age After the Fontan Procedure Completed · 97 cited
  2. Phase 4 Rivaroxaban With Diosmin in Long-term Treatment of Deep Vein Thrombosis Completed · 38 cited
  3. Phase 3 Microvascular and Antiinflammatory Effects of Rivaroxaban Compared to Aspirin in Type-2 Diabetic Patients With Subclinical Inflammation and High Cardiovascular Risk Completed · 21 cited
  4. Phase 3 Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Symptomatic Peripheral Artery Disease Undergoing Peripheral Revascularization Procedures of the Lower Extremities Completed · 19 cited
  5. Phase 4 Switching From DAPT to Dual Pathway Inhibition With Low-dose Rivaroxaban in Adjunct to Aspirin in Patients With Coronary Artery Disease Completed · 10 cited
  6. Phase 3 Rivaroxaban vs. Warfarin for Post Cardiac Surgery Atrial Fibrillation Completed · 9 cited
  7. Phase 4 A Study of Rivaroxaban for Early Discharge of Low Risk Pulmonary Embolism From the Emergency Department Completed
  8. Phase 4 Rivaroxaban Versus Warfarin in the Evaluation of Progression of Coronary Calcium Completed
  9. Phase 4 Combined Topical Tranexamic Acid With Floseal® in Total Knee Arthroplasty Completed
  10. Phase 3 RAMBLE - Rivaroxaban vs. Apixaban for Heavy Menstrual Bleeding Completed
  11. Phase 3 Regulation of Coagulation in Orthopedic Surgery to Prevent Deep Vein Thromboembolism (DVT) and Pulmonary Embolism (PE). A Study of BAY59-7939 in the Prevention of Venous Thrombo Embolism (VTE) in Subjects Undergoing Elective Total Knee Replacement. Completed
  12. Phase 3 Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion Completed
  13. Phase 3 Once - Daily Oral Direct Factor Xa Inhibitor Rivaroxaban In The Long-Term Prevention Of Recurrent Symptomatic Venous Thromboembolism In Patients With Symptomatic Deep-Vein Thrombosis Or Pulmonary Embolism. The Einstein-Extension Study Completed
  14. Phase 3 A Study Exploring Two Treatment Strategies in Patients With Atrial Fibrillation Who Undergo Catheter Ablation Therapy Completed
  15. Phase 3 Efficacy and Safety of Rivaroxaban for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation Completed
  16. Phase 3 Switching Drug Therapy for the Prevention of Blood Clot Formation From Enoxaparin to Rivaroxaban After Orthopedic Surgery for Either Total Hip or Total Knee Replacement Completed
  17. Phase 3 Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Deep Vein Thrombosis - The EINSTEIN DVT Study Completed
  18. Phase 3 Venous Thromboembolic Event (VTE) Prophylaxis in Medically Ill Patients Completed
  19. Phase 3 An Efficacy and Safety Study of Rivaroxaban With Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Patients With Non-Valvular Atrial Fibrillation Completed
  20. Phase 3 Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Pulmonary Embolism - The EINSTEIN PE Study Completed
  21. Phase 2 Phase 2 Study of Rivaroxaban Reversal by Ciraparantag as Measured by WBCT Completed
  22. Phase 2 A Study to Compare the Safety of Rivaroxaban Versus Acetylsalicylic Acid in Addition to Either Clopidogrel or Ticagrelor Therapy in Participants With Acute Coronary Syndrome Completed
  23. Phase 2 Rivaroxaban for Treatment in Venous or Arterial Thrombosis in Neonates Completed
  24. Phase 2 The Effect of Rivaroxaban in Sickle Cell Disease Completed
  25. Phase 2 A Healthy Volunteer Pharmacokinetics (PK)/Pharmacodynamics (PD), Safety and Tolerability Study of Andexanet in Healthy Japanese and Caucasian Subjects Completed
  26. Phase 2 Rivaroxaban Versus Warfarin in Acute Ischemic Stroke With Atrial Fibrillation Completed
  27. Phase 2 Oral Rivaroxaban in Children With Venous Thrombosis Completed
  28. Phase 2 Rivaroxaban in Combination With Aspirin Alone or With Aspirin and a Thienopyridine in Patients With Acute Coronary Syndromes (The ATLAS ACS TIMI 46 Trial) Completed
  29. Phase 2 EINSTEIN Junior Phase II: Oral Rivaroxaban in Young Children With Venous Thrombosis Completed
  30. Phase 2 Deep Vein Thrombosis Treatment With the Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients Using a Strong CYP 3A4 Inducer Completed
  31. Phase 2 Efficacy of RIvaroxaban for Prevention of Venous Thromboembolism After Knee Arthroscopy Completed
  32. Phase 1 Impact of Steady State Cobicistat and Darunavir/Cobicistat on the Pharmacokinetics and Pharmacodynamics of Oral Anticoagulants (Rivaroxaban, Apixaban) in Health Volunteers Completed
  33. Phase 1 Switching Study From Warfarin to Rivaroxaban Completed
  34. Phase 1 Bioequivalence Study in Healthy Subjects, 2*5 mg Tablets Rivaroxaban Versus 1*10 mg Tablet Rivaroxaban Completed
  35. N/A An Exploratory stuDy of effectIveneSs and Safety of rivarOxaban in Patients With Left VEntricular Thrombus (R-DISSOLVE) Completed
  36. N/A Treatment Patterns and Bleeding Risk of Anticoagulants in Patients With Venous Thromboembolism in Korea Completed
  37. N/A Medical Need of OAC Reversal Completed
  38. N/A Prediction of the COBRRA AF Anticoagulant Trial in Healthcare Claims Data Completed
  39. N/A Non-interventional, Retrospective Cohort Study to Explore OAC Treatment in Korea Completed
  40. N/A A Study to Learn About the Effects of Medicines That Help in Thinning the Blood in People With Atrial Fibrillation (AF) Between 2016 and 2020 in France Completed
  41. N/A Direct Oral Anticoagulants (DOACs) Versus LMWH +/- Warfarin for VTE in Cancer Completed
  42. N/A Apixaban Drug Utilization Study In Stroke Prevention In Atrial Fibrillation (Spaf) Completed

Showing the 48 most-cited and recently-updated of 48 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Post-hoc analysis links lower systolic BP to higher cardiovascular risk in AF and stable CAD
Cardiology RCT
Post-hoc analysis links lower systolic BP to higher cardiovascular risk in AF and stable CAD Lower blood pressure linked to higher risk in AF patients with heart disease
A post-hoc analysis of the AFIRE trial (n=2135) found patients with atrial fibrillation and stable coronary artery disease who had baseline …
Patients with atrial fibrillation and low blood pressure face a 38% higher risk of heart attack, stroke, or death compared to those with hig…
Apr 6, 2026
FDA Approves Xarelto (rivaroxaban) for multiple indications including stroke prevention in nonvalvular atrial fibrillation and treatment of VTE
Cardiology FDA Approval
FDA Approves Xarelto (rivaroxaban) for multiple indications including stroke prevention in nonvalvular atrial fibrillation and treatment of VTE FDA approves a new blood thinner called Xarelto for several heart and clot conditions
The FDA approved rivaroxaban (Xarelto), a factor Xa inhibitor, for multiple indications including reducing stroke risk in nonvalvular atrial…
FDA approves new blood thinner Xarelto to prevent dangerous clots in heart conditions, deep vein issues, and after major surgeries.
FDA Mar 31, 2026
FDA Approves Xarelto (rivaroxaban) for Thromboprophylaxis in Pediatric Patients After Fontan Procedure
Cardiology FDA Approval
FDA Approves Xarelto (rivaroxaban) for Thromboprophylaxis in Pediatric Patients After Fontan Procedure FDA approves Xarelto to help prevent blood clots in children with certain heart conditions
The FDA approved rivaroxaban (Xarelto) for thromboprophylaxis in pediatric patients aged 2 years and older with congenital heart disease who…
FDA approves Xarelto to prevent dangerous blood clots in children aged 2 and older born with heart defects who have had Fontan surgery.
FDA Mar 31, 2026
TRACK trial to assess low-dose rivaroxaban for MACE in advanced CKD/dialysis patients
Nephrology Phase III
TRACK trial to assess low-dose rivaroxaban for MACE in advanced CKD/dialysis patients Can a low-dose blood thinner protect people with advanced kidney disease from heart attacks and strokes?
The TRACK trial is a global, quadruple-blind, placebo-controlled phase 3 study evaluating low-dose rivaroxaban (2.5 mg) for reducing major a…
A new global study tested whether a low-dose blood thinner safely protects people with advanced kidney disease from heart attacks and stroke…
CT.gov Mar 30, 2026